Corpus Intelligence IC Memo — ST MICHAELS MEDICAL HOSPITAL LLC 2026-04-26 12:30 UTC
IC Memo — ST MICHAELS MEDICAL HOSPITAL LLC
Investment Committee Memorandum | TX | 5 beds | Grade D | EBITDA uplift $615K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST MICHAELS MEDICAL HOSPITAL LLC

CCN 670314 | FORT BEND, TX | 5 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

ST MICHAELS MEDICAL HOSPITAL LLC is a 5-bed community hospital in FORT BEND, TX with $8.2M in net patient revenue and a 5.0% operating margin. The hospital serves a payer mix of 31.5% Medicare, 0.0% Medicaid, and 68.5% commercial.

Thesis: Turnaround. Our ML models identify $615K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.0% to 12.4% (+746bps).

Net Revenue HCRIS$8.2M
Current EBITDA COMPUTED$410K
Operating Margin COMPUTED5.0%
Occupancy HCRIS5.0%
Revenue / Bed COMPUTED$1.6M
Net-to-Gross HCRIS18.1%
Distress Probability MLnan%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
50
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 5.0% places it above the state median. Among 50 size-comparable peers (2-10 beds), the median margin is -8.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (2-10), prioritizing same-state peers. 50 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST MICHAELS MEDICAL HOSPITAL L (Target)TX5$8.2M5.0%
FRANCISCAN HEALTH HAMMONDIN10$117.7M-4.3%
OCONTO HOSPITAL & MEDICAL CENTWI10$80.4M1.1%
SUMMIT PACIFIC MEDICAL CENTERWA10$73.6M9.1%
PHYSICIANS MEDICAL CENTERIN10$60.0M24.9%
SAMUEL SIMMONDS MEMORIAL HOSPIAK10$57.8M-50.0%
JOYCE EISENBERG KEEFER MEDICALCA10$52.9M18.8%
PARK PLACE SURGERY CENTERLA10$51.6M15.4%
JONES REGIONAL MEDICAL CTRIA10$43.5M0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $615K (746bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$173K+210bp18mo
Denial Rate Reduction12.0%6.5%$167K+203bp12mo
Cost to Collect4.5%2.5%$165K+200bp12mo
A/R Days Reduction5200.0%3800.0%$100K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+12bp6mo

5. EBITDA Bridge

Net Collection Rate
$173K
Denial Rate Reduction
$167K
Cost to Collect
$165K
A/R Days Reduction
$100K
Clean Claim Rate
$10K
Total EBITDA Uplift$615K
Current EBITDA$410K
+ RCM Uplift+$615K
Pro Forma EBITDA$1.0M
Current Margin5.0%
Pro Forma Margin12.4%
WC Released (1x)$316K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$631K$8.9M14.03x69.6%
Base (11x exit)10.0x11.0x$631K$9.9M15.76x73.6%
Bull Case9.0x11.0x$568K$12.2M21.44x84.6%
Bull (12x exit)9.0x12.0x$568K$13.5M23.69x88.3%
Bear Case11.0x10.0x$694K$5.6M8.03x51.7%
Bear (11x exit)11.0x11.0x$694K$6.4M9.16x55.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 5.0%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 50 hospitals with 2-10 beds
  • Same-state prioritization (n=18)
  • Comp margins: P25=-35.5% / P50=-8.7% / P75=4.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.